Comparative study shows excellent intermediate vision results, high levels of spectacle independence and minimal photic phenoma at night.
The Diffractiva Diff-aA MIOL is currently under clinical evaluation in a multicentre study in which seven participating University or Private Clinics in France, Austria, UK and Libanon are taking part. A total enrollment of 45 patients (90 eyes) with bilateral cataract and eligible for MIOL implantation has been targeted. Ophthalmic examinations including refraction, monocular and binocular visual acuity for far, intermediate (1 m) and near (40 cm) distances have been scheduled at 1-month, 3-months and 6-months postoperatively. Evaluation of contrast sensitivity and defocus curve has been scheduled at 6 months postoperatively, patient satisfaction (quality-of-life questionnaire) at 3 and 6-months postoperatively.